PARP1 and ovarian carcinoma: In addition, HMGB3 facilitated the development of PARPi resistance by directly interacting with PARP1 in ovarian cancer cells, and the inhibition of HMGB3 combined with PARPi might have broad prospects in the clinical therapy of ovarian cancer.